Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Research Journal

The science, examined.

Plain-spoken notes on the compounds we supply — what the literature shows, how to read a COA, and the protocols that protect your data. Cited, never hyped.

All Bioregulators Comparisons Guides Gut Hormonal Immune In the news Metabolic & longevity Methods & QC Nootropics Regulation Sexual health Skin & matrix Sleep Tissue repair
EloraTZP vs Retatrutide: What the Three Datasets Show In the news
Latest

EloraTZP vs Retatrutide: What the Three Datasets Show

A Lilly slide shows 29% weight loss in 31 weeks with eloralintide plus tirzepatide. Only 3 of 12 had data, and it can't be compared with retatrutide's 28.3%.

Oct 2026 · 6 min read
In the news

Novo’s $1.4 Billion Bet on Oral Macrocycles: What a Deal Validates and What It Doesn’t

Novo signed with Orbis for up to $1.4bn on oral macrocycles. Against two 2026 approvals, what the deal establishes and what it does not.

Sep 2026 · 7 min read
In the news

Chemically Pure, Biologically Contaminated: What Endotoxin Testing Measures

Three 2026 recalls traced to one contaminated raw material show why chemical purity and biological contamination are different questions.

Sep 2026 · 7 min read
In the news

It Was Sold as Retatrutide. The Regulator’s Lab Found No Retatrutide at All

The TGA tested a vial sold as retatrutide after a hospitalisation: no retatrutide, and about eight times the semaglutide of registered products.

Sep 2026 · 8 min read
In the news

Flmodafinil and Fladrafinil on the 2026 WADA Prohibited List

WADA named flmodafinil and fladrafinil under class S6 in 2026. Why it adds examples rather than a new ban, and what it means for…

Sep 2026 · 8 min read
The Global Peptide Manufacturing Arms Race Has Begun In the news

The Global Peptide Manufacturing Arms Race Has Begun

Samsung Biologics opened a CHF 1.46 billion tender for PolyPeptide on 15 September, with 55.65% of shares already committed. CordenPharma closed its AmbioPharm acquisition…

Sep 2026 · 7 min read
From Grey Market to $80 Billion TAM? Why Wall Street Is Suddenly Paying Attention to Peptides In the news

From Grey Market to $80 Billion TAM? Why Wall Street Is Suddenly Paying Attention to Peptides

An FT Lex column put potential US peptide sales near $80bn a year. Analysts quoted by Reuters put the market regulatory change would unlock…

Sep 2026 · 8 min read
After Antibody-Drug Conjugates, Are Peptide-Drug Conjugates Next? In the news

After Antibody-Drug Conjugates, Are Peptide-Drug Conjugates Next?

TwoStep Therapeutics cleared an IND for TS-104, a peptide-drug conjugate delivering MMAE through an integrin-binding peptide, alongside a $62.5m Series A. What PDCs change…

Sep 2026 · 7 min read
Semaglutide in Children Aged 6 to 11: What the STEP Young Phase 3 Trial Actually Found In the news

Semaglutide in Children Aged 6 to 11: What the STEP Young Phase 3 Trial Actually Found

Novo Nordisk reported that 40.4% of children aged 6 to 11 fell below the obesity threshold on semaglutide against 0% on placebo. What that…

Sep 2026 · 9 min read
BPC-157 Is Entering a Phase 1 Trial After Rotator Cuff Repair: What NCT07803250 Will Actually Test In the news

BPC-157 Is Entering a Phase 1 Trial After Rotator Cuff Repair: What NCT07803250 Will Actually Test

A Phase 1 study of BPC-157 after arthroscopic rotator cuff repair was posted to ClinicalTrials.gov on 3 September 2026. It is not the first…

Sep 2026 · 12 min read
Mimrylo (Rusfertide): The FDA Just Approved a Peptide That Mimics a Hormone Most People Have Never Heard Of In the news

Mimrylo (Rusfertide): The FDA Just Approved a Peptide That Mimics a Hormone Most People Have Never Heard Of

On 28 August 2026 FDA approved Mimrylo (rusfertide) for polycythemia vera — the first hepcidin-mimetic peptide medicine. The mechanism is iron restriction, and it…

Aug 2026 · 5 min read
Avexitide: The Peptide That Blocks the Receptor Ozempic Activates In the news

Avexitide: The Peptide That Blocks the Receptor Ozempic Activates

Avexitide is a GLP-1 receptor antagonist — the same target as semaglutide, the opposite direction. In August 2026 it cut severe hypoglycaemic events by…

Aug 2026 · 5 min read
Previous Page 1 of 3 Next

New research, in your inbox

Occasional, considered notes on the compounds and the literature. No noise.

Subscribe & earn 500 points